Peter J Allen


Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA


  1. Allen P, D Angelica M, Gonen M, Jaques D, Coit D, Jarnagin W, et al. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg. 2006;244:572-82 pubmed
    ..Malignancy within mucinous tumors is associated with size, and small mucinous tumors are very unlikely to be malignant. ..
  2. request reprint
    Allen P, Brennan M. The management of cystic lesions of the pancreas. Adv Surg. 2007;41:211-28 pubmed
    ..Continued improvements in cross-sectional imaging and endoscopic techniques and further investigation into markers in the serum and cyst fluid should allow better identification of mucinous subtypes. ..
  3. Pulvirenti A, Rao D, McIntyre C, Gonen M, Tang L, Klimstra D, et al. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2018;: pubmed publisher
    ..CgA has a limited role as a diagnostic biomarker for well-differentiated PanNETs. An elevated CgA level may have prognostic value but its role should be further investigated with respect to other known pathological factors. ..
  4. Kunstman J, Goldman D, Gonen M, Balachandran V, D Angelica M, Kingham T, et al. Outcomes after Pancreatectomy with Routine Pasireotide Usage. J Am Coll Surg. 2018;: pubmed publisher
    ..3%, approximating the effect observed in the randomized trial of pasireotide during routine surgical practice. ..
  5. Al Efishat M, Attiyeh M, Eaton A, Gonen M, Basturk O, Klimstra D, et al. Progression Patterns in the Remnant Pancreas after Resection of Non-Invasive or Micro-Invasive Intraductal Papillary Mucinous Neoplasms (IPMN). Ann Surg Oncol. 2018;25:1752-1759 pubmed publisher
    ..These patients represent a high-risk group and should undergo long-term radiographic surveillance. ..
  6. Leal J, Kingham T, D Angelica M, Dematteo R, Jarnagin W, Kalin M, et al. Intraductal Papillary Mucinous Neoplasms and the Risk of Diabetes Mellitus in Patients Undergoing Resection Versus Observation. J Gastrointest Surg. 2015;19:1974-81 pubmed publisher
    ..Degree of dysplasia, not the amount of resected pancreas, was associated with increased risk of DM, suggesting that the presence or development of DM may be a marker of malignant progression. Confirmatory studies are required. ..
  7. Sadot E, Doussot A, O Reilly E, Lowery M, Goodman K, Do R, et al. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015;22:3512-21 pubmed publisher
    ..Nearly one third of the patients who had been initially identified as having stage 3 pancreatic carcinoma and had been treated with FOLFIRINOX responded radiographically and underwent tumor resection. ..
  8. Allen P. Operative resection is currently overutilized for cystic lesions of the pancreas. J Gastrointest Surg. 2014;18:182-3 pubmed publisher
  9. Allen P. The management of intraductal papillary mucinous neoplasms of the pancreas. Surg Oncol Clin N Am. 2010;19:297-310 pubmed publisher
    ..This article describes the radiologic and histopathologic classification system of IPMN; the biologic behavior of these lesions, and the diagnostic testing most commonly used, and discusses the current treatment controversies. ..

More Information


  1. Dudeja V, Allen P. Premalignant cystic neoplasms of the pancreas. Semin Oncol. 2015;42:70-85 pubmed publisher
    ..We provide an overview of the key features used in diagnosis and in predicting malignancy. Particular attention is given to the natural history and management decision making. ..
  2. Root A, Allen P, Tempst P, Yu K. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Cancers (Basel). 2018;10: pubmed publisher
    ..The magnitude of the clinical translational challenge is uncertain, but interdisciplinary cooperation within the PDAC community is poised to confront it. ..
  3. Sadot E, Reidy Lagunes D, Tang L, Do R, Gonen M, D Angelica M, et al. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. Ann Surg Oncol. 2016;23:1361-70 pubmed publisher
    ..In this study, no patient who was initially observed developed metastases or died from disease after a median follow-up of 44 months. Observation for stable, small, incidentally discovered PanNET is reasonable in selected patients. ..
  4. Al Efishat M, Allen P. Therapeutic Approach to Cystic Neoplasms of the Pancreas. Surg Oncol Clin N Am. 2016;25:351-61 pubmed publisher
    ..Research is focusing on the development of pre-operative markers for identifying high risk lesions, which will spare patients with low-risk or benign lesions the risks of pancreatectomy. ..
  5. Allen P. The diagnosis and management of cystic lesions of the pancreas. Chin Clin Oncol. 2017;6:60 pubmed publisher
    ..This chapter will highlight the challenges with diagnosis and management of patients who present with cystic neoplasms of the pancreas. ..
  6. Pak L, D Angelica M, Dematteo R, Kingham T, Balachandran V, Jarnagin W, et al. Natural History of Patients Followed Radiographically with Mucinous Cysts of the Pancreas. J Gastrointest Surg. 2017;21:1599-1605 pubmed publisher
    ..Appropriately selected patients with mucinous pancreatic cysts can be safely followed with serial surveillance with a low risk of malignant progression. ..
  7. Pak L, Schattner M, Balachandran V, D Angelica M, Dematteo R, Kingham T, et al. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. HPB (Oxford). 2018;20:182-187 pubmed publisher
    ..In this study of selected patients who underwent IgG4 testing, 9% of elevated IgG4 patients had PDAC. The overreliance on IgG4 as diagnostic for AIP may lead to mis-diagnosis and delayed treatment for PDAC. ..
  8. Allen P, Qin L, Tang L, Klimstra D, Brennan M, Lokshin A. Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg. 2009;250:754-60 pubmed publisher